EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice

Wan-Ying Du, Hiroki Masuda, Koji Nagaoka, Tomohiko Yasuda, Komei Kuge, Yasuyuki Seto, Kazuhiro Kakimi, Sachiyo Nomura iD

Gastric Cancer · 2024

DOI: 10.1007/s10120-024-01514-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2024. Verfasst von Wan-Ying Du und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Immune Checkpoint Inhibitors, Mice, Inbred C57BL, Peritoneal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science London, Princess Takamatsu Cancer Research Fund, The University of Tokyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer immunotherapy aims to unleash the immune system’s potential against cancer cells, providing sustained relief for tumors responsive to immune checkpoint inhibitors (ICIs). While promising in gastric cancer (GC) trials, the efficacy of ICIs diminishes in the context of peritoneal dissemination. Our objective is to identify strategies to enhance the impact of ICI treatment specifically for cases involving peritoneal dissemination in GC.

Methods

The therapeutic efficacy of anti-PD1, CTLA4 treatment alone, or in combination was assessed using the YTN16 peritoneal dissemination tumor model. Peritoneum and peritoneal exudate cells were collected for subsequent analysis. Immunohistochemical staining, flow cytometry, and bulk RNA-sequence analyses were conducted to evaluate the tumor microenvironment (TME). A Janus kinase inhibitor (JAKi) was introduced based on the pathway analysis results.

Results

Anti-PD1 and anti-CTLA4 combination treatment (dual ICI treatment) demonstrated therapeutic efficacy in certain mice, primarily mediated by CD8 + T cells. However, in mice resistant to dual ICI treatment, even with CD8 + T cell infiltration, most of the T cells exhibited an exhaustion phenotype. Notably, resistant tumors displayed abnormal activation of the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway compared to the untreated group, with observed infiltration of macrophages, neutrophils, and Tregs in the TME. The concurrent administration of JAKi rescued CD8 + T cells function and reshaped the immunosuppressive TME, resulting in enhanced efficacy of the dual ICI treatment.

Conclusion

Dual ICI treatment exerts its anti-tumor effects by increasing tumor-specific CD8 + T cell infiltration, and the addition of JAKi further improves ICI resistance by reshaping the immunosuppressive TME.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsImmune Checkpoint InhibitorsMice, Inbred C57BLPeritoneal NeoplasmsDrug Resistance, NeoplasmJanus Kinase InhibitorsTumor MicroenvironmentAnimalsMiceCD8-Positive T-LymphocytesCTLA-4 AntigenHumansFemaleProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Immune checkpoint blockerImmunotherapyJAK pathwayPeritoneal metastasis

Substanzen

Immune Checkpoint InhibitorsJanus Kinase InhibitorsCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
  • Department of Gastrointestinal Surgery, Nippon Medical School, Tokyo, Japan.
  • Department of Immunotherapeutics, The University of Tokyo Hospital, Tokyo, Japan.
  • Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. sachiyo.nomura1012@gmail.com.
  • Department of Clinical Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-Ku, Tokyo, 142-8501, Japan. sachiyo.nomura1012@gmail.com.

ORCID-Profile: Sachiyo Nomura

Förderung

  • Japan Society for the Promotion of Science London
  • Princess Takamatsu Cancer Research Fund
  • The University of Tokyo

Zitieren

APA

Du, W. Y., Masuda, H., Nagaoka, K., Yasuda, T., Kuge, K., Seto, Y., Kakimi, K., & Nomura, S. (2024). Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice. Gastric Cancer. https://doi.org/10.1007/s10120-024-01514-5

Vancouver

Du WY, Masuda H, Nagaoka K, Yasuda T, Kuge K, Seto Y, et al. Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice. Gastric Cancer. 2024. doi:10.1007/s10120-024-01514-5

BibTeX
@article{Du2024,
  author = {Du, Wan-Ying and Masuda, Hiroki and Nagaoka, Koji and Yasuda, Tomohiko and Kuge, Komei and Seto, Yasuyuki and Kakimi, Kazuhiro and Nomura, Sachiyo},
  title = {Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice},
  journal = {Gastric Cancer},
  year = {2024},
  doi = {10.1007/s10120-024-01514-5}
}
Kostenlos starten →